BioRestorative Therapies, Inc. (BRTX)
1.56
-0.04
(-2.50%)
USD |
NASDAQ |
Oct 20, 16:00
1.60
+0.04
(+2.56%)
Pre-Market: 20:00
BioRestorative Therapies Research and Development Expense (TTM) : 9.374M for March 31, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 9.374M |
| December 31, 2025 | 9.162M |
| September 30, 2025 | 8.193M |
| June 30, 2025 | 6.918M |
| March 31, 2025 | 5.985M |
| December 31, 2024 | 5.329M |
| September 30, 2024 | 4.351M |
| June 30, 2024 | 3.841M |
| March 31, 2024 | 3.452M |
| December 31, 2023 | 3.625M |
| September 30, 2023 | 3.618M |
| June 30, 2023 | 3.797M |
| March 31, 2023 | 3.970M |
| December 31, 2022 | 3.513M |
| September 30, 2022 | 3.005M |
| June 30, 2022 | 2.254M |
| March 31, 2022 | 1.339M |
| December 31, 2021 | 0.7291M |
| September 30, 2021 | 0.7415M |
| June 30, 2021 | 0.7551M |
| March 31, 2021 | 0.8558M |
| December 31, 2020 | 0.8768M |
| September 30, 2020 | 1.115M |
| June 30, 2020 | 1.274M |
| March 31, 2020 | 1.454M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.722M |
| September 30, 2019 | 1.682M |
| June 30, 2019 | 1.630M |
| March 31, 2019 | 1.561M |
| December 31, 2018 | 1.513M |
| September 30, 2018 | 1.383M |
| June 30, 2018 | 1.516M |
| March 31, 2018 | 1.754M |
| December 31, 2017 | 2.152M |
| September 30, 2017 | 2.660M |
| June 30, 2017 | 2.825M |
| March 31, 2017 | 2.823M |
| December 31, 2016 | 2.884M |
| September 30, 2016 | 2.761M |
| June 30, 2016 | 2.720M |
| March 31, 2016 | 2.564M |
| December 31, 2015 | 2.105M |
| September 30, 2015 | 1.828M |
| June 30, 2015 | 1.503M |
| March 31, 2015 | 1.344M |
| December 31, 2014 | 1.431M |
| September 30, 2014 | 1.484M |
| June 30, 2014 | 1.608M |
| March 31, 2014 | 1.687M |
| December 31, 2013 | 1.594M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Myriad Genetics, Inc. | 105.80M |
| CareDx, Inc. | 79.87M |
| Natera, Inc. | 787.38M |
| Exagen, Inc. | 6.466M |
| Sera Prognostics, Inc. | 12.27M |